Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating restated by Wedbush in a research note issued on Thursday, Benzinga reports. They currently have a $165.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 90.29% from the stock’s previous close.

Several other equities analysts also recently weighed in on ORKA. Guggenheim reiterated a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. UBS Group raised their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $86.71 on Thursday. The company’s 50 day simple moving average is $96.79 and its 200 day simple moving average is $75.32. Oruka Therapeutics has a fifty-two week low of $14.89 and a fifty-two week high of $115.51. The firm has a market capitalization of $5.74 billion, a P/E ratio of -42.71 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Sell-side analysts expect that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Klein sold 2,452 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total value of $234,680.92. Following the completion of the transaction, the chief executive officer directly owned 923,128 shares in the company, valued at approximately $88,352,580.88. This represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 533 shares of the company’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $95.75, for a total transaction of $51,034.75. Following the completion of the transaction, the senior vice president owned 14,219 shares of the company’s stock, valued at $1,361,469.25. This trade represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 122,950 shares of company stock worth $11,528,806 in the last three months. 23.49% of the stock is owned by insiders.

Institutional Trading of Oruka Therapeutics

Institutional investors have recently bought and sold shares of the company. Engineers Gate Manager LP purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at about $350,000. Arizona State Retirement System grew its holdings in Oruka Therapeutics by 45.0% during the second quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock valued at $825,000 after purchasing an additional 2,691 shares during the period. Nykredit A S bought a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $29,000. Braidwell LP bought a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $26,473,000. Finally, Natural Investments LLC bought a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $202,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $165 price target, implying substantial potential upside from the referenced $89.93 level. Tickerreport analyst rating article
• Positive Sentiment: HC Wainwright also reaffirmed its “buy” rating and assigned a $120 price target, indicating continued analyst confidence in Oruka’s pipeline and valuation. StreetInsider analyst rating article
• Positive Sentiment: Oruka reported encouraging Week 28 results from the Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. PASI 100 responses increased to 71.4% and PASI 90 responses to 87.3%, despite no additional dosing after Week 4, suggesting durable and deepening treatment effects. Oruka EVERLAST-A Week 28 results
• Positive Sentiment: Placebo-crossover patients achieved PASI 90 and PASI 100 response rates comparable to patients initially treated with ORKA-001, while the therapy continued to show a favorable safety and tolerability profile. Additional EVERLAST-A data are expected in December 2026, with EVERLAST-B results expected in the fourth quarter. MarketScreener trial results
• Negative Sentiment: Oruka shares fell after the Week 28 release despite improving psoriasis responses. The reaction suggests investors may have already anticipated strong data, or may be focused on the need for additional validation from upcoming 52-week and follow-on trial results. Yahoo Finance market reaction

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.